Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests

Clinical Chemistry

Volumn 46, Issue 12, 2000, Pages 2027-2049

  Dufour, D R ^a   Lott, J A ^a   Nolte, F S ^a   Gretch, D R ^a   Koff, R S ^a   Seeff, L B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME;

ENZYME ANALYSIS; HUMAN; INTERNET; LABORATORY DIAGNOSIS; LIVER FUNCTION TEST; LIVER INJURY; MEDICAL INFORMATION; PATIENT MONITORING; PERFORMANCE; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; STANDARDIZATION;

HEPATITIS C VIRUS;

EID: 0033637463     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.12.2027     Document Type: Review

References (266)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Projecting the future healthcare burden from hepatitis C in the United States
3. Rising incidence of hepatocellular carcinoma in the United States
4. European specifications for imprecision and inaccuracy compared with operating specifications that assure the quality required by US CLIA proficiency-testing criteria
5. Introduction: Strategies to set global quality specifications in laboratory medicine
6. Determination and application of desirable analytical performance goals: The ISO/TC 212 approach
7. The application of theoretical goals based on biological variation data in proficiency testing
8. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring
9. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C
10. Donor transaminase and recipient hepatitis - Impact on blood transfusion services
11. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The Transfusion-Transmitted Viruses Study
12. Proficiency testing of enzymes. Charting the way toward standardization
13. On the pyridoxal-5'-phosphate stimulation of AST and ALT in serum and erythrocytes of patients undergoing chronic hemodialysis and with kidney transplants
14. The clinical significance of alterations in transaminase activities of serum and other body fluids
15. Measurement of aminotransferases. Part 1. Aspartate aminotransferase
16. Biochemical assessment of liver function
17. Aspartate aminotransferase isoenzymes
18. Aspartate aminotransferase and alanine aminotransferase activities in plasma: Statistical distributions, individual variations and reference values
19. Serum activity of mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis
20. Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and nonalcoholic liver disease
21. Effect of serum pyridoxine deficiency on serum and liver transaminases in experimental liver injury in the rat
22. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in Hep G-2 cells
23. Optimization of methods for aspartate aminotransferase and alanine aminotransferase
24. Review of pyridoxal phosphate and the transaminases in liver disease
25. 6 in patients with chronic renal failure on regular hemodialysis
26. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
27. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors
28. Approved recommendation (1987) on the theory of reference values, part 6. Presentation of observed values related to reference values
29. Determination of reference ranges for serum enzymes via a large interlaboratory survey
30. Medically useful criteria for analytic performance of laboratory tests
31. Biochemistry of alkaline phosphatase isoenzymes
32. Alkaline phosphatase
33. Alkaline phosphatase isoenzymes: Recent progress
34. Alkaline phosphatase
35. Biochemistry of alkaline phosphatase isoenzymes
36. Multiple forms of acid and alkaline phosphatases: Genetics, expression and tissue modification
37. Structure of the human liver/bone/kidney alkaline phosphatase gene
38. The behavior of infused placental alkaline phosphatase in human subjects
39. Serum alkaline phosphatase after fat ingestion: An immunological study
40. Turnover of skeletal alkaline phosphatase in humans
41. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women
42. Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells
43. The mechanism of the increase in the activity of liver alkaline phosphatase in experimental cholestasis: Measurement of an increased enzyme concentration by immunochemical titration
44. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: Significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver
45. Measurement of total alkaline phosphatase activity in human serum
46. Measurement of total alkaline phosphatase activity in human serum
47. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum
48. Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity
49. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases
50. Prospective study of clinical and biochemical features of symptomatic choledocholithiasis
51. Immunological cross-reactivity of γ-glutamyl transpeptidase from human and rat kidney
52. γ-Glutamyl transpeptidase: Catalytic, structural and functional aspects
53. Electrophoretic variants of alanine aminopeptidase, alkaline phosphatase, and γ-glutamyl transferase in urine
54. Relationship between γ-glutamyl transpeptidase and mean urinary alcohol levels in alcoholics while drinking and after alcohol withdrawal
55. Predictive value of γ-glutamyl transpeptidase in various liver diseases
56. Hepatic γ-glutamyl transferase release: Effect of bile salt and membrane structure modification
57. Liver γ-glutamyl transferase activity in viral liver disease
58. Progress in the enzyme diagnosis of liver disease: Reality or illusion
59. γ-Glutamyltransferase and its isoenzymes: Progress and problems
60. γ-Glutamyl transpeptidase in diseases of the liver and bone
61. Serum γ-glutamyltranspeptidase activity in myocardial ischaemia
62. Functional and clinical aspects of γ-glutamyltranspeptidase and its isoenzymes: A critical review of recent progress
63. Serum γ-glutamyl transpeptidase. Evaluation in screening of hospitalized patients
64. IFCC methods for measurement of enzymes. Part 4. IFCC methods for γ-glutamyltransferase [(γ-glutamyl)-peptide: Amino acid γ-glutamyltransferase, EC 2.3.2.2]
65. Hereditary jaundice and disorders of bilirubin metabolism
66. Unconjugated hyperbilirubinemia: Physiologic evaluation and experimental approaches to therapy
67. Influence of albumin on the extravascular distribution of unconjugated bilirubin
68. Origin of mammalian biliprotein and rearrangement of bilirubin glucuronides in vivo in the rat
69. What can we learn from analysis of serum bilirubin
70. Clinical chemistry and physiology of bilirubin
71. Intrahepatic cholestasis
72. Serum bilirubins in hepatobiliary disease: Comparison with other liver function tests and changes in the portobstructive period
73. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
74. Diagnosis of Gilbert's syndrome
75. Assessment of the fundamental accuracy of the Jendrassik-Grof total and direct bilirubin assays
76. Conjugated bilirubin: A better indicator of impaired hepatobiliary excretion than direct bilirubin
77. Delta bilirubin: Absorption spectra, molar absorptivity, and reactivity in the diazo reaction
78. The measurement of bilirubin fractions in serum
79. Light has a greater effect on direct bilirubin measured by the bilirubin oxidase method than by the diazo method
80. The measurement of fractionated bilirubin by Ektachem film slides - Method validation and comparison of conjugated bilirubin measurements with direct bilirubin in obstructive and hepatocellular jaundice
81. Inaccurate values for direct bilirubin with some commonly used direct bilirubin procedures
82. 'Direct', total bilirubin tests: Contemporary problems
83. Serum and urine albumin: A progress report on their measurement and clinical significance
84. Gender related differences in liver function and integrity tests
85. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C
86. Serum albumin by dye-binding: Bromcresol green or bromcresol purple?
87. Bromcresol purple method for serum albumin gives falsely low values in patients with renal insufficiency
88. Bromcresol purple dye-binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure
89. Bromcresol purple dye-binding methods underestimate albumin that is carrying covalently bound bilirubin
90. Effects of serum-isolated vs. synthetic bilirubin-albumin complexes on dye-binding methods for estimating serum albumin
91. Electroimmunoassay of albumin in human serum: Accuracy and long-term precision
92. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
93. Implications of use of low international sensitivity index thromboplastins in prothrombin time testing
94. Determination of the mean normal prothrombin time for assessment of international normalized ratios. Usefulness of lyophilized plasma
95. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR)
96. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: Comparison with the prothrombin time ratio
97. Assessment of the validity of the INR system for patients with liver impairment
98. Prothrombin time in liver failure: Time, ratio, activity percentage, or International Normalized Ratio?
99. Acquired vitamin K-dependent carboxylation deficiency in liver disease
100. Laboratory identification of ischemic hepatitis (shock liver)
101. Ischemic hepatitis: Clinical and laboratory observations of 34 patients
102. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction
103. Serious hepatitis A: An analysis of patients hospitalized during an epidemic in the United States
104. Alcoholic hepatitis
105. Early indicators of prognosis in fulminant hepatic failure
106. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection
107. The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study
108. Use of different thromboplastin reagents causes greater variability in international normalized ratio results than prolonged room temperature storage of specimens
109. The reliability of manufacturer-determined, instrument specific international sensitivity index values for calculating the international normalized ratio
110. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of oral anticoagulant therapy
111. System ISI calibration: A universally applicable scheme is possible only when coumarin plasma calibrants are used
112. Thromboplastin related differences in the determination of international normalized ratio: A cause for concern?
113. Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy
114. Screening INR deviation of local prothrombin time systems
115. A cross-Canada survey of prothrombin time testing. Does the establishment of local ISI values improve the accuracy of international Normalized Ratio reporting?
116. Effects of Helicobacter pylori eradication therapy on hyperammonemia in patients with liver cirrhosis
117. Helicobacter pylori and plasma ammonia levels in cirrhotics: Role of urease inhibition by acetohydroxamic acid
118. Inborn errors of urea synthesis
119. Grade 1 Reye's syndrome - Outcome and predictors of progression to deeper coma grades
120. Studies of the blood ammonia in liver disease - Its diagnostic, prognostic, and therapeutic significance
121. Ammonia: Key factor in the pathogenesis of hepatic encephalopathy
122. Hepatic detoxification and hepatic function in chronic active hepatitis with and without cirrhosis
123. Blood methanetriol in alcoholic liver disease with and without hepatic encephalopathy
124. The involvement of ammonia with the mechanisms that enhance GABA-ergic neurotransmission in hepatic failure
125. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy
126. Hyperammonemia without portal systemic shunting does not resemble hepatic encephalopathy
127. Determination of blood ammonia in biological fluids
128. Preanalytical increase of ammonia in blood specimens from healthy subjects
129. Ammonia. Chemistry survey set C-B
130. Host immune response to hepatitis A virus
131. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A
132. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A
133. Hepatitis A in Greenland: Importance of specific antibody testing in epidemiologic surveillance
134. Seroepidemiology of hepatitis A in the United States
135. Vaccination against hepatitis A: Comparison of different short-term immunization schedules
136. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine
137. Hepatitis A vaccine: Persistence of antibodies 5 years after the first vaccination
138. Hepatitis A: Detection by immune electron microscopy of virus-like antigen associated with acute illness
139. Detection of hepatitis A viral antigen by radioimmunoassay
140. Hepatitis viruses
141. IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus
142. Hepatitis B virus
143. Frequency and significance of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated severe chronic active hepatitis B
144. Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis
145. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army
146. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine
147. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
148. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen
149. Significance of antibody to hepatitis B core antigen in blood donors as determined by their serologic response to hepatitis B vaccine
150. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination
151. Concomitant hepatitis B surface antigen and antibody in thirteen patients
152. Hepatitis B and D viruses
153. Persistent viremia after recovery from self-limited acute hepatitis B
154. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff
155. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg
156. New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus
157. Quantitative measurement of serum HCV-RNA in patients with chronic hapatitis C; Comparison between Amplicor HCV monitor system and branched DNA signal amplification assay
158. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA
159. Evaluation of third-generation screening and confirmatory assays for HCV antibodies
160. Diagnostic tests for hepatitis C
161. Persistent hepatitis C viremia after acute self-limited posttransfusion hepatitis
162. Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: Impact of epitope variation and relationship to detection of HCV RNA in blood
163. Mortality and morbidity of transfusion-associated non-A, non-B hepatitis and type C hepatitis: And NHLBI multicenter study
164. Perinatal hepatitis C virus transmission: Maternal risk factors and optimal timing of diagnosis
165. Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection
166. A pattern of 5-1-1 and c100-3 only on hepatitis C (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors
167. Long-term follow-up and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels
168. Significance of indeterminate third-generation hepatititis C virus recombinant immunoblot assay
169. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
170. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
171. Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assays
172. Significance of NS3 and NS5 antigens in screening for HCV antibody
173. GB virus type C/hepatitis G virus infection n French blood donors with anti-NS5 isolated reactivities by recombinant immunoblot assay for hepatitis C virus
174. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen
175. Comparison of competitive and non-competitive reverse transcriptiohn-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA
176. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays
177. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification assay: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients
178. Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus
179. Effects of anticoagulants and storage of blood samples on efficacy of the polymerase chain reaction assay for hepatitis C virus
180. Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA
181. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized clinical trials
182. Is an 'a la carte' combination interferon α-2b plus ribavirin regimen possible for first line treatment in patients with chronic hepatitis C?
183. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
184. Racial differences in response to therapy with interferon in chronic hepatitis C
185. The impact of race on response to anti-viral therapy in patients with chronic hepatitis C
186. Methods for determining the hepatitis C virus genotype
187. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test
188. Hepatitis C virus genotyping by means of a 5'-UR/core line probe assays and molecular analysis of untypeable specimens
189. Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers or probes
190. Determination of hepatitis C virus genotype in the United States by cleavage fragment length polymorphism analysis
191. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region
192. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay
193. Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: Evidence for transient or occult superinfection with HCV of different genotypes
194. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States
195. Application of six hepatitis C genotyping systems to sera from chronic hepatitis C patients in the United States
196. Epidemiology of hepatitis delta virus: Overview
197. A hepatitis E variant from the United States: Molecular characterization and transmission in cynomolgus macaques
198. Assay development of diagnostic tests for hepatitis E
199. Evaluation of assays for antibody to hepatitis E virus by a serum panel
200. Seroreactivity to hepatitis E virus in areas where the disease is not endemic
201. Evidence for widespread infection of wild rats with hepatitis E virus in the United States
202. Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population
203. Current databases on biological variation: Pros, cons and progress
204. Analytic goals, concentration relationships, and state of the art for clincal laboratory precision
205. Diurnal variation of serum alanine transaminase activity in chronic liver disease
206. Circadian rhythms of serum concentrations of 12 enzymes of clinical interest
207. Biological variation in clinical chemistry. An update: Collated data, 1988-1991
208. Intra-individual variation in serum from patients with chronic liver diseases
209. Biological variability of 26 clinical chemistry analytes in elderly people
210. Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study
211. Body mass index and liver enzyme activity in serum
212. Factors associated with serum alanine aminotransaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C
213. Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening
214. Creatine kinase and glutamic oxoacetic transaminase activity in serum: Kinetics of change with exercise and effect of physical conditioning
215. Effects of habitual exercise on routine laboratory tests
216. Anabolic steroid induced hepatotoxicity: Is it overstated?
217. Serumconstituents analyses: Effect of duration and temperature of storage of clotted blood
218. Stability of serum alanine aminotransferase activity
219. Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum
220. Stability of AST and ALT assays in Tris buffers
221. Effect of pyridoxal 5-phosphate on the stability of alanine aminotransferase
222. Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase
223. University of Virginia case conference. Macroamylase, macro creatine kinase, and other macroenzymes
224. Intestinal alkaline phosphatase and the ABO blood group system: A new aspect
225. The contribution of the intestinal mucosa to the total serum alkaline phosphatase activity
226. Human intestinal alkaline phosphatase; Release to the blood is linked to lipid absorption, but removal from the blood is not linked to lipoprotein clearance
227. Factors associated with serum alkaline phosphatase level
228. A serum biochemical profile of normal pregnancy
229. Effects of oral contraceptives on routine laboratory tests
230. The Tromso Study - Distribution and population determinants of γ-glutamyltransferase
231. γ-Glutamyltransferase activity in plasma: Statistical distributions, individual variations, and reference intervals
232. Serum γ-glutamyl transpeptidase activity in viral hepatitis: Suppression in pregnancy and by birth control pills
233. Biochemical and haematological markers of alcohol intake
234. Alterations of lipid metabolism in healthy volunteers during long-term ethanol intake
235. Serum γ-glutamyl transpeptidase and chronic alcoholism - Influence of alcohol ingestion and liver disease
236. Bilirubinemia and fasting
237. Effects of food ingestion on routine laboratory tests
238. Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia)
239. The use of evacuated tubes for blood collection in oral anticoagulant control
240. Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care
241. Reliability of delayed INR determination: Implications for decentralized anticoagulant care with off-site blood sampling
242. The effects of sodium citrate anticoagulant concentration, storage on or off cellular matrix, and specimen age on prothrombin time INR using a low ISI (1.06) rabbit brain thromboplastin
243. Effect of 3.2% vs. 3 8% sodium citrate on routine coagulation testing
244. Reference intervals for blood ammonia in healthy subjects, determined by microdiffusion
245. Arteriovenous difference of blood ammonia in uremic patients under hemodialysis
246. Gender differences in blood ammonia response during exercise
247. Influences of specimen processing and storage conditions on results for plasma ammonia
248. Deamidation of glutamate by increased plasma γ-glutamyltransferase is a source of rapid ammonia formation in blood and plasma specimens
249. Idiopathic hyperammonemia: A frequently lethal complication of bone marrow transplantation
250. Plasma ammonia in patients with acute leukemia
251. Asymptomatic hyperammonemia in children treated with valproic acid
252. The role of ammonia toxicity in the post transurethral prostatectomy syndrome